Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees
Healthy Q3 For 'Big Three'
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.
You may also be interested in...
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
As well as buying Origimm, the French giant will also apply its mRNA vaccine platform, acquired through the recent $3.2bn acquisition of Translate Bio, to discover and develop other acne vaccines, aided by the Vienna-headquartered firm's know-how in the field.